JP7240512B2 - Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 - Google Patents

Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 Download PDF

Info

Publication number
JP7240512B2
JP7240512B2 JP2021545411A JP2021545411A JP7240512B2 JP 7240512 B2 JP7240512 B2 JP 7240512B2 JP 2021545411 A JP2021545411 A JP 2021545411A JP 2021545411 A JP2021545411 A JP 2021545411A JP 7240512 B2 JP7240512 B2 JP 7240512B2
Authority
JP
Japan
Prior art keywords
antibody
patients
cervical cancer
pharmaceutical composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530599A5 (https=
JP2022530599A (ja
Inventor
マシュー・ジー・フュリー
イザレル・ロウィ
メリッサ・ディブヤ・マティアス
ナズミ・アリス・ヤマ－デン
ウェン・フュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022530599A publication Critical patent/JP2022530599A/ja
Priority to JP2022179201A priority Critical patent/JP2023011902A/ja
Publication of JP2022530599A5 publication Critical patent/JP2022530599A5/ja
Application granted granted Critical
Publication of JP7240512B2 publication Critical patent/JP7240512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021545411A 2020-05-26 2021-05-25 Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 Active JP7240512B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022179201A JP2023011902A (ja) 2020-05-26 2022-11-09 Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063029757P 2020-05-26 2020-05-26
US63/029,757 2020-05-26
US202063069942P 2020-08-25 2020-08-25
US63/069,942 2020-08-25
US202163160074P 2021-03-12 2021-03-12
US63/160,074 2021-03-12
US202163174474P 2021-04-13 2021-04-13
US63/174,474 2021-04-13
US202163181434P 2021-04-29 2021-04-29
US63/181,434 2021-04-29
US202163185881P 2021-05-07 2021-05-07
US63/185,881 2021-05-07
PCT/US2021/034000 WO2021242728A1 (en) 2020-05-26 2021-05-25 Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022179201A Division JP2023011902A (ja) 2020-05-26 2022-11-09 Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法

Publications (3)

Publication Number Publication Date
JP2022530599A JP2022530599A (ja) 2022-06-30
JP2022530599A5 JP2022530599A5 (https=) 2022-11-29
JP7240512B2 true JP7240512B2 (ja) 2023-03-15

Family

ID=76859703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545411A Active JP7240512B2 (ja) 2020-05-26 2021-05-25 Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
JP2022179201A Pending JP2023011902A (ja) 2020-05-26 2022-11-09 Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022179201A Pending JP2023011902A (ja) 2020-05-26 2022-11-09 Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法

Country Status (11)

Country Link
US (1) US20210403567A1 (https=)
EP (1) EP4157464A1 (https=)
JP (2) JP7240512B2 (https=)
KR (1) KR20230015954A (https=)
CN (1) CN115666724A (https=)
AU (1) AU2021280245A1 (https=)
CA (1) CA3168738A1 (https=)
IL (1) IL298273A (https=)
MX (1) MX2022014734A (https=)
TW (1) TWI899236B (https=)
WO (1) WO2021242728A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318426A (en) * 2022-08-02 2025-03-01 Regeneron Pharma Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
TWI887800B (zh) * 2022-10-12 2025-06-21 美商默沙東有限責任公司 經由皮下投予抗pd1抗體以治療癌症之組合物及方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
KR102410090B1 (ko) * 2014-02-21 2022-06-16 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
ES2791950T3 (es) 2015-02-03 2020-11-06 Ventana Med Syst Inc Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
SG11201808626WA (en) 2016-04-07 2018-10-30 Chemocentryx Inc Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
WO2020018789A1 (en) * 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Ａｎｎａｌｓ ｏｆ Ｏｎｃｏｌｏｇｙ ２９（ｓｕｐｐｌ＿１０） （２０１８）， Ｘ２７－２８
Ｃｌｉｎｉｃａｌ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ ２６ （２０２０．０３）， １０２５－１０３３
Ｅｘｐｅｒｔ Ｏｐｉｎ Ｄｒｕｇ Ｄｉｓｃｏｖ．，２０１８，Ｖｏｌ．１３，Ｎｏ．５，ｐ．４４５－４５７
ｆｒｏｎｔｉｅｒｓ ｉｎ Ｐｈａｒｍａｃｏｌｏｇｙ １０ （２０１９）， Ａｒｔｉｃｌｅ ６５
Ｇｙｎｅｃｏｌ．Ｏｎｃｏｌ．，２０２０，Ｖｏｌ．１５９，Ｎｏ．２，ｐ．３２２－３２８
Ｇｙｎｅｃｏｌｏｇｉｃ Ｏｎｃｏｌｏｇｙ １５７ （２０２０．０１）， １６１－１６６
Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｏｎｃｏｌｏｇｙ ３８（１５＿ｓｕｐｐｌ）（２０２０．０５．２０）， １００１８

Also Published As

Publication number Publication date
US20210403567A1 (en) 2021-12-30
AU2021280245A1 (en) 2022-12-08
JP2023011902A (ja) 2023-01-24
MX2022014734A (es) 2023-03-15
TWI899236B (zh) 2025-10-01
JP2022530599A (ja) 2022-06-30
WO2021242728A1 (en) 2021-12-02
CN115666724A (zh) 2023-01-31
EP4157464A1 (en) 2023-04-05
CA3168738A1 (en) 2021-12-02
KR20230015954A (ko) 2023-01-31
TW202210098A (zh) 2022-03-16
IL298273A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
JP7624033B2 (ja) Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法
JP7384949B2 (ja) 肺癌の処置のための抗ｐｄ－１抗体
US20220249659A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
JP2023011902A (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
IL323023A (en) Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
US20250326846A1 (en) Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
CN117043193A (zh) 通过施用新辅助pd-1抑制剂治疗癌症的方法
US20250270321A1 (en) Methods of treating lung cancer by administering a pd-1 inhibitor
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
EA049388B1 (ru) Способы лечения базально-клеточной карциномы путем введения антитела или его антигенсвязывающего фрагмента, специфически связывающихся с pd-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220809

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221109

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221109

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20221109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221117

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221209

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221213

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20221213

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221220

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230221

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230303

R150 Certificate of patent or registration of utility model

Ref document number: 7240512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150